Share this article
Share this article
ABBOTT PARK, Ill., Jan. 20, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as transcatheter mitral valve repair (TMVr), to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure. The decision significantly increases the number of people eligible for insurance coverage for mitral valve repair with MitraClip, enabling broader access to the device. As the first and only TEER device approved by the U.S. Food and Drug Administration (FDA) and reimbursed by Medicare for primary mitral regurgitation, physicians have increasingly relied on the therapy to improve survival and quality of life for their patients. Today s decision improves insurance coverage for people with secondary MR who need treatment with
Medicare Expands Coverage for MitraClip in Heart Failure Patients
New national reimbursement significantly expand access to transcatheter mitral valve repair procedures for secondary mitral regurgitation
January 20, 2021 The U.S. Centers for Medicare and Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for the Abbott MitraClip to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure.
The procedure is known as transcatheter edge-to-edge repair (TEER), but is also referred to as transcatheter mitral valve repair (TMVR).
The CMS decision significantly increases the number of people eligible for insurance coverage for mitral valve repair with MitraClip, enabling broader access to the device. As the first TEER device approved by the U.S. Food and Drug Administration (FDA) and reimbursed by Medicare for primary mitral regurgitation, physicians have increasingly relied on the therapy to improv
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip Device
Abbott today announced that the U.S. Centers for Medicare & Medicaid Services revised its National Coverage Determination to expand coverage for transcatheter edge-to-edge repair also referred to as transcatheter mitral valve repair to include patients with secondary mitral regurgitation resulting from heart failure. The decision significantly increases the number of people eligible for insurance coverage for …
– Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as transcatheter mitral valve repair (TMVr), to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure. The decision significantly increases the number of people eligible for insurance coverage for mitral val
want. the last thing they want to worry about is health insurance. if they on their parent s policy, they can stay on it until the age of 26. that alleviates a lot of pressure. it requires group and individual plans to provide effective appeals process for coverage determinations. in every insurance company there is someone who determines what are we going to cover? are we going to cover this test? are we going to cover that test? they ll decide how much coverage they re going to give a client or patient. now there s an appeals process that the consumer can go through, an avenue to follow. you don t just take no for an answer anymore. i know the conservatives and the republicans have been oh, 2014, it s a bad bill. this will affect americans off the bat.